News Related to IgE-Mediated Peanut Allergy

Related coverage linked through entity extraction aliases.

Novartis Remibrutinib Shows Positive Results in Chronic Inducible Urticaria Trial

Feb 23, 2026

Novartis announced positive topline results from its Phase III RemIND trial of remibrutinib in chronic inducible urticaria, meeting the primary endpoint for the three most prevalent types of the condition with significantly higher complete response rates versus placebo.

Novartis Remibrutinib Achieves Phase III Endpoint in Chronic Inducible Urticaria

Feb 18, 2026

Novartis reported positive Phase III RemIND trial results showing remibrutinib achieved complete response in three types of chronic inducible urticaria. The company has submitted a supplemental New Drug Application to the FDA for symptomatic dermographism.